$304.96-0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Just reported
From Krystal Biotech, Inc.'s results release of November 2, 2026; its quarterly report has since been filed.
Actual
$127.3M
+30% y/y
+6.8% q/q
Guided
—
No guide given
Actual
$2.05
-23% y/y
+15% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $127.3M | $97.8M | +30.21% |
| Profit | $63.1M | $79.4M | -20.53% |
| Profit per share | $2.05 | $2.66 | -22.93% |
| Free Cash Flow | $90.3M | $38M | +137.79% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Krystal Biotech, Inc. reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Krystal Biotech, Inc.’s Item 2.02 8-K filed November 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$71.1M
+72% y/y
+22% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.